No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for PMV Pharmaceuticals, Inc. (PMVP) stock was $1.68 as of Oct 6, 2026, 12:25 PM EDT, down 5.90% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +23.5% · 3-year avg -34.0%/yr · 5-year avg -43.2%/yr
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients.
Biotechnology · Princeton, NJ
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.31
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.34
vs Estimate
$-0.40
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PMVP | $89.33M | $1.68 | -5.90% | +23.49% | -43.17% | N/A | N/A |
| 2ICCC | $89.34M | $9.88 | +1.28% | +54.20% | +0.65% | +2.46% | vs PMVP |
| 3RLYB | $89.21M | $16.81 | -0.53% | +271.55% | -35.80% | N/A | vs PMVP |
| 4NMRA | $90.60M | $0.49 | -6.91% | -71.12% | N/A | N/A | vs PMVP |
| 5EQ | $90.73M | $1.44 | -1.03% | -3.34% | -26.99% | N/A | vs PMVP |
| 6ECOR | $91.51M | $10.15 | +0.20% | +101.52% | -8.10% | N/A | vs PMVP |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$4.20
+150.7% upside
Low
$3.00
Current
$1.68
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.40 | $-0.34 | $-0.28 | 3 |
| Quarter ending Dec 2026 | $-0.37 | $-0.28 | $-0.19 | 2 |
| Quarter ending Mar 2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Quarter ending Jun 2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.33 | $-1.20 | $-0.98 | 3 |
| FY 2027 | $-1.11 | $-0.90 | $-0.59 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.26M | $2.92M | $3.59M | 5 |
| FY 2027 | $4.81M | $6.21M | $7.62M | 3 |
